本帖最后由 老马 于 2012-1-13 21:20 编辑
' c4 b/ T# X0 { R" K/ U7 a! b) x8 O& w# t( v( Y' B
爱必妥和阿瓦斯丁的比较. G# b+ q4 G- q6 n# o
; d. K7 w# R9 A7 d) H6 P- n8 Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg// A$ z4 Y8 N: Z7 J5 U
' c U' j6 J" p2 |! c4 ^: r7 v; T3 P
6 |9 g1 H# y! Xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ T/ X5 m7 `9 H1 s) }+ Q2 O X
==================================================( m! x/ B* W& Q8 [7 p0 }
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* T. |# N8 ?, l/ ^# r3 H# S& p* XPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, R V2 S( o! KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# J9 q) \' ?+ {) [+ Q6 K9 G
|